SVB Leerink Comments on Intercept Pharmaceuticals, Inc.’s Q1 2023 Earnings (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 earnings per share estimates for shares of Intercept Pharmaceuticals in a research note issued on Thursday, March 2nd. SVB Leerink analyst T. Smith forecasts that the biopharmaceutical company will post earnings per share of ($0.72) for the quarter. SVB Leerink currently has a “Market Perform” rating and a $18.00 target price on the stock. The consensus estimate for Intercept Pharmaceuticals’ current full-year earnings is ($2.82) per share. SVB Leerink also issued estimates for Intercept Pharmaceuticals’ Q2 2023 earnings at ($0.68) EPS and Q3 2023 earnings at ($0.31) EPS.

ICPT has been the topic of a number of other reports. Raymond James raised their target price on shares of Intercept Pharmaceuticals from $26.00 to $28.00 in a research note on Sunday. HC Wainwright lowered their target price on shares of Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, November 16th. SVB Securities upped their target price on shares of Intercept Pharmaceuticals from $17.00 to $18.00 in a report on Friday. Royal Bank of Canada increased their price objective on Intercept Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Friday. Finally, Needham & Company LLC lifted their price objective on Intercept Pharmaceuticals from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Intercept Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $26.00.

Intercept Pharmaceuticals Trading Up 0.5 %

ICPT stock opened at $20.68 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.46 and a debt-to-equity ratio of 2.07. The business’s 50-day moving average is $17.40 and its 200 day moving average is $16.05. Intercept Pharmaceuticals has a 12-month low of $10.81 and a 12-month high of $21.86. The stock has a market cap of $856.57 million, a price-to-earnings ratio of 3.20 and a beta of 1.29.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ICPT. BlackRock Inc. increased its stake in Intercept Pharmaceuticals by 8.0% during the 3rd quarter. BlackRock Inc. now owns 2,936,187 shares of the biopharmaceutical company’s stock worth $40,960,000 after acquiring an additional 217,833 shares during the period. Vanguard Group Inc. increased its holdings in Intercept Pharmaceuticals by 7.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,706,414 shares of the biopharmaceutical company’s stock worth $37,755,000 after purchasing an additional 197,255 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Intercept Pharmaceuticals by 1,124.8% in the third quarter. Point72 Asset Management L.P. now owns 1,559,183 shares of the biopharmaceutical company’s stock valued at $21,751,000 after acquiring an additional 1,431,883 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Intercept Pharmaceuticals by 20.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 780,945 shares of the biopharmaceutical company’s stock valued at $10,894,000 after acquiring an additional 135,254 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Intercept Pharmaceuticals by 87.9% in the third quarter. Renaissance Technologies LLC now owns 739,200 shares of the biopharmaceutical company’s stock valued at $10,312,000 after acquiring an additional 345,800 shares in the last quarter. 81.09% of the stock is owned by institutional investors and hedge funds.

About Intercept Pharmaceuticals

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.